https://www.renbio.com/news_and_events/renbio-highlights-potential-of-dna-based-glp-1-therapies-for-durable-weight-loss/
Biotech News & Events
- RenBio Highlights Potential of DNA-Based GLP-1 Therapies for Durable Weight Loss
- RenBio’s Dr. Rachel Liberatore Presents at ASGCT Annual Meeting in Boston
- Exciting progress in the fight against obesity
- RenBio is excited to provide an update on our ultra long-acting GLP-1 receptor agonist program.
- RenBio Announces New Awards to Support Continued Development of Its Novel, DNA-Based MYO TechnologyTM Platform for Antiviral Applications
- ASGCT 27th Annual Meeting in Baltimore
- RenBio at AntibodyTherapeutics Xchange 2024
- RenBio at BIO CEO & Investor Conference
- Renbio at Biotech Showcase
- AI in Action E413: Rachel Liberatore, President & Chief Scientific Officer at RenBio
- RenBio’s Rachel Liberatore to Present at Vaccines Summit 2023
- RenBio’s Highlight at the Life Sciences Summit: A Showcase of Innovation
- RenBio Attends New York BIO Annual Meeting
- RenBio’s Rachel Liberatore at LSX – Partnering for Life Science Executives in Boston
- RenBio attended BIO International Convention
- RenBio to attend BIO International Convention in Boston
- RenBio attends the Keystone Symposia
- RenBio presents at World Congress on Electroporation
- RenBio Secures Grants for DNA Therapeutics
- RenBio with Global Rights for COVID-19 Bispecific Antibody
- RenBio’s New Address
- RenBio participates in NIH Summit
- Nucleic Acid Antibody Delivery: BioWorld Review
- RenBio Scientists Review DNA Antiviral Delivery
- RenBio’s COO, Neal Padte, presents on “Antibody Gene Transfer by In Vivo Electroporation” at the “3rd World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies.”
- RenBio featured in Nature OUTLOOK: The genetic shortcut to antibody drugs
- RenBio’s DARPA-Funded Tech Spotlighted at Meeting
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017